Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 55,500 shares of common stock to three (3) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Covered in this story
Analyst targets on Kura Oncology Inc
- Citizens JMP: $9.83 → $24 by Oct 2027 · Market Outperform via Investing.com
- UBS: $10.7 → $15 by Oct 2027 · Buy via Investing.com
- JPMorgan: $10.7 → $30 by Oct 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kura Oncology Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.